More on cetuximab in head and neck cancer [7]

New England Journal of Medicine

Volumn 357, Issue 21, 2007, Pages 2201-2203

  Mell, Loren K ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; LETTER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 36348959692     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc071540     Document Type: Letter

References (5)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
2. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004;96:1128-32.
3. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-62.
4. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-35.
5. Freidlin B, Korn EL. Testing treatment effects in the presence of competing risks. Stat Med 2005;24:1703-12.